Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021
HomeCLINICAL TRIALS, STUDIES, DATAEmbrace Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial: 1st Patients Enrolled

Embrace Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial: 1st Patients Enrolled

March 30, 2021

Embrace Hydrogel Embolic System (HES™) is a global randomized clinical trial for the treatment of hypervascular tumors.

As demonstrated previously in the completed First-in-Human (FIH) study, Embrace Hydrogel Embolic System (HES) was effective at embolizing malignant and benign hypervascular tumors by blocking tumor blood supply with complete technical success and persistent embolizationi as noted in imaging follow up at 30-days.

“I am pleased to be evaluating this new technology for hypervascular tumor embolization,” commented Dr. Gerard Goh, Head of Interventional Radiology at The Alfred Hospital, Melbourne Australia, and President of the Interventional Radiology Society of Australasia (IRSA). “While participating in the First-in-Human study prior to this trial, Embrace showed great promise with good control, favorable patient outcomes, and no tumor revascularization. We are excited to be the first center to enroll in this global, randomized trial.”

A hypervascular tumor, which can be found in the liver, kidney, or elsewhere, has an increased number of blood vessels relative to other tissues. These tumors are often associated with low survival rates.ii Due to the increased risk of bleeding, hypervascular tumors can be challenging to remove.

Transcatheter arterial embolization (TAE) and transarterial chemoembolization (cTACE) are established treatments for hypervascular tumors, particularly for patients with limited progressive disease. Embrace HES, an investigational product, is a liquid embolic designed to deeply penetrate the tumor vascular bediii, solidify, and stop blood flow.

The Embrace HES embolization uses no solvents, does not need sizing to the vessel diameter, and eliminates the possibility of catheter entrapment. Its main components are water and polyethylene glycol (PEG). PEG has a long history of safe use in implantable medical devices.

“We are thrilled to be the first center in the US to treat a patient on this study. Embrace’s predictability helps me embolize the tumor while avoiding non-target embolization,” added Dr. Edgar D. St. Amour, Interventional Radiologist from CARTI Cancer Center in Little Rock. “I look forward to continued evaluation of this new advancement in treating hypervascular tumors.”

“I would like to thank Drs. Goh and St. Amour, and our other global trial sites for their efforts and collaboration in achieving this significant clinical milestone,” said Amar Sawhney, Instylla CEO. “Hypervascular tumors can cause significant morbidity and mortality. At Instylla, we are focused on creating novel solutions to improve outcomes for these patients.”


References

i Manuscript submitted for publication

ii Hotta, Naoki & Ayada, Minoru & Okumura, Akihiko & Ishikawa, Tetsuya & Sato, Ken & Oohashi, Tomohiko & Hijikata, Yasutaka & Kakumu, Shinichi. (2009). Hepatocellular Carcinoma 11 and a Half Years after the Resolution of Chronic Hepatitis C Virus Infection Successfully Treated with Interferon. Case reports in gastroenterology. 3. 175-181. 10.1159/000225244.

iii Ganguli S, Lareau R, Jarrett T, Soulen MC, A Water-based Liquid Embolic: Evaluation of Safety and Efficacy in a Rabbit Kidney Model, Journal of Vascular and Interventional Radiology (2021)

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy